Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | VNN1 | O95497 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25658103 | 0.82 | KDM4E (0.60) | TSHRCYP2C9CYP2C19ALDH1A1KDM4E | |
| SCHEMBL27394992 | 0.82 | CYP3A4 (0.72) | CYP2C9CYP2C19ALDH1A1CYP3A4KMT2A | |
| SCHEMBL8096850 | 0.82 | CYP3A4 (0.72) | CYP2C9CYP2C19ALDH1A1CYP3A4KMT2A | |
| SCHEMBL30460501 | 0.81 | CYP3A4 (0.57) | TSHRCYP2C9CYP2C19ALDH1A1KDM4E | |
| SCHEMBL30460504 | 0.81 | CYP3A4 (0.57) | TSHRCYP2C9CYP2C19ALDH1A1KDM4E | |
| SCHEMBL30460513 | 0.81 | CYP3A4 (0.57) | TSHRCYP2C9CYP2C19ALDH1A1KDM4E | |
| SCHEMBL30460584 | 0.81 | CYP3A4 (0.57) | TSHRCYP2C9CYP2C19ALDH1A1KDM4E | |
| SCHEMBL14669652 | 0.80 | ALDH1A1 (0.55) | TSHRCYP2C9CYP2C19ALDH1A1CYP3A4 | |
| SCHEMBL30460491 | 0.79 | POLB (0.64) | TSHRCYP2C9CYP2C19ALDH1A1KDM4E | |
| SCHEMBL30460499 | 0.79 | POLB (0.64) | TSHRCYP2C9CYP2C19ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130028843-A1 | KALLIKREIN 7 MODULATORS | NOVARTIS AG (CH) | 2013-01-31 | — | — | US | disclosed |
| US-8309596-B2 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2012-11-13 | — | — | US | disclosed |
| US-8309596-B2 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2012-11-13 | — | — | US | disclosed |
| US-20100256144-A1 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2010-10-07 | — | — | US | disclosed |
| US-20100256144-A1 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2010-10-07 | — | — | US | disclosed |
| WO-2009000878-A1 | KALLIKREIN 7 MODULATORS | NOVARTIS AG (CH) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130028843-A1 | KALLIKREIN 7 MODULATORS | KLK7, KLK5, KLKB1 | TSHR 2691/4885CYP2C9 3235/4885CYP2C19 3214/4885 |
| US-20100256144-A1 | Kallikrein 7 modulators | KLK7, KLK5, KLKB1 | TSHR 2691/4885CYP2C9 3235/4885CYP2C19 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.